Related resources
Full-text held externally
- PMID: 20628238
- UKPMCID: 20628238
- DOI: 10.1159/000317775
Search for item elsewhere
University researcher(s)
Academic department(s)
Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial.
Reich, Kristian; Ortonne, Jean-Paul; Kerkmann, Urs; Wang, Yanxin; Saurat, Jean-Hilaire; Papp, Kim; Langley, Richard; Griffiths, Christopher E M
Dermatology (Basel, Switzerland). 2010;221(2):172-8.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 20628238
- UKPMCID: 20628238
- DOI: 10.1159/000317775
Abstract
BACKGROUND: The EXPRESS study demonstrated the initial efficacy of infliximab in psoriasis affecting the skin and nails. OBJECTIVE: To further assess how patients with a positive initial response to infliximab respond to 1 year of continuous infliximab treatment. METHODS: A retrospective analysis of patients with moderate-to-severe plaque and nail psoriasis who initiated and continued infliximab treatment up to week 46 was conducted. RESULTS: Among all nail psoriasis patients receiving 1 year of infliximab (n = 186), 74.6 and 54.1% achieved at least 75 or 90% improvement in the Psoriasis Area and Severity Index (PASI) at week 50. These PASI-75 (n = 138) and PASI-90 (n = 100) responders had respective mean improvements from baseline to week 50 of 93.6 and 97.3% for the PASI, 90.6 and 94.1% for the Dermatology Life Quality Index (DLQI) and 78.2 and 80.3% for the Nail Psoriasis Severity Index (NAPSI). CONCLUSIONS: Infliximab treatment for 1 year produced sustained improvement in PASI, DLQI and NAPSI scores.